Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review

Archives of Dermatology

Volumn 146, Issue 10, 2010, Pages 1141-1150

  Mella, José Manuel ^a   Perret, María Clara ^a   Manzotti, Matías ^a   Catalano, Hugo Norberto ^a   Guyatt, Gordon ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; SELF ASSEMBLED MONOLAYER;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; LIBIDO DISORDER; MALE TYPE ALOPECIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCALP HAIR; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ALOPECIA; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALOPECIA; FINASTERIDE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77958162673     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.256     Document Type: Review

References (41)

1. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1-11.
2. Norwood OT. Hair Transplant Surgery. Springfield, IL: Charles C Thomas Publishers; 1973:3-16.
3. Budd D, Himmelberger D, Rhodes T, Cash TE, Girman CJ. The effects of hair loss in European men: a survey in four countries. Eur J Dermatol. 2000;10 (2):122-127.
4. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926-931.
5. Girman CJ, Rhodes T, Lilly FR, et al. Effects of self-perceived hair loss in a community sample of men. Dermatology. 1998;197(3):223-229. (Pubitemid 28445819)
6. Küster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol. 1984;11(5, pt 1):921-926.
7. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995;98(1A):95S-98S.
8. Sawaya ME. Steroid chemistry and hormone controls during the hair follicle cycle. Ann N Y Acad Sci. 1991;642:376-384.
9. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296-300.
10. Rittmaster RS. Finasteride. N Engl J Med. 1994;330(2):120-125.
11. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550-554.
12. Whiting DA, Waldstreicher J. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4(3):282-284.
13. Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol. 1999;141(3):481-491. (Pubitemid 29448409)
14. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
15. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7.
16. Mantzoros CS, Georgiadis EI, Trichopoulos D. Contribution of dihydrotestosterone to male sexual behaviour. BMJ. 1995;310(6990):1289-1291.
17. Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol. 2001;15(5):418-421. (Pubitemid 33040112)
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1): 1-12. (Pubitemid 26120810)
19. Barber BL, Kaufman KD, Kozloff RC, Girman CJ, Guess HA. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatolog Treat. 1998;9:181-186.
20. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996;14(4):713-721.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
22. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176(8):1091-1096. (Pubitemid 46649731)
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
24. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129(1):174-181. (Pubitemid 43265259)
25. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
26. Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. Int J Dermatol. 1999;38(12):928-930. (Pubitemid 30002746)
27. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.
28. Kaufman KD, Olsen EA, Whiting D, et al; Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4, pt 1):578-589.
29. Kawashima M, Hayashi N, Igarashi A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol. 2004;14(4):247-254.
30. Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005;31(10):1268-1276.
31. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6, pt 1):930-937.
32. Olsen EA, Hordinsky M, Whiting D, et al; Dutasteride Alopecia Research Team. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.
33. Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517-523.
34. Price VH, Menefee E, Sanchez M, Kaufman KD, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006;55(1):71-74.
35. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555-563.
36. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol. 2002;12 (1):32-37.
37. Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804-810.
38. Whiting DA, Olsen EA, Savin R, et al; Male Pattern Hair Loss Study Group. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150-160.
39. Yang SX, Ji SZH, Chen W, et al. A double blind randomized placebo controlled clinical trial of finasteride in the treatment of androgenetic alopecia [in Chinese]. Chin J Clin Pharmacol. 2002;18(1):3-6.
40. Broniarczyk-Dyla G, Prusinska-Bratos M, Dubla-Berner M, Langner A, Placek W. 12-Months treatment of men with androgenetic alopecia with finasteride: multicentre Polish study. Przegl Dermatol. 2002;89(5):377-380. (Pubitemid 35415755)
41. Oxman A, Guyatt G. Users' Guides to the Medical Literature, II: Beyond the Basics: When to Believe a Subgroup Analysis. Chicago, IL: AMA Press; 2002.